3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
13
Neoplasm Metastasis
3
Neoplasms by Site
2
Neoplasms
2
Breast Diseases
2
Advanced Breast Cancer
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Skin Diseases
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Lymphoma, Follicular
1
Endometrial Neoplasms
1
ER+ HER2- Advanced Breast Cancer
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Biliary Tract Neoplasms
1
Interventions
pembrolizumab
44
Carboplatin
28
Cisplatin
26
Paclitaxel
24
Bevacizumab
21
human papillomavirus vaccine, L1 type 16, 18
16
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
14
atezolizumab
11
Papillomavirus Vaccines
11
Nivolumab
10
tisotumab vedotin
8
Vaccines, Synthetic
8
Gemcitabine
8
Colposcopy
8
Topotecan
7
fludarabine
6
Vaccines
6
Injections
6
Cyclophosphamide
6
spartalizumab
5
balstilimab
5
Pemetrexed
5
Irinotecan
5
Fulvestrant
5
Docetaxel
5
zimberelimab
4
durvalumab
4
Vinorelbine
4
Ipilimumab
4
Interleukin-2
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Uterine Cervical Neoplasms
×
AZD9833
×
Clear all
NCT04644068
2026-02-19
PETRA
AstraZeneca
Phase 1/2
Active not recruiting
702 enrolled